

VTE Diseases Committee meeting

Date: 17/12/2018

Location: NICE – London

Minutes: Final

Committee members present:	
Susan Bewley (SB) (Chair)	Present for all
Frances Akor (FA)	Present for all
Michelle Greene (MG)	Present for all
Sam Hare (SH)	Present for all
Carol Hooper (CH)	Present for all
Daniel Horner (DH)	Present for all
Nigel Langford (NL)	Present until part way through item 6
Terry McCormack (TM)	Present for all
Karen Sheares (KS)	Present until part way through item 6
Hazel Trender (HT)	Present for all
Astrid Ullrich-Boereboom (AU)	Present for all

In attendance:		
Sohaib Ashraf (SA)	NICE – Health Economist	Present until part way through item 6
Thomas Jarratt (TJ)	NICE – Technical Analyst	Present for all
Ben Johnson (BJ)	NICE – Health Economist	Present for all
Justine Karpusheff (JK)	NICE – Guidelines Commissioning Manager	Present until part way through item 6
Marie Harrisingh (MH)	NICE – Technical Adviser	Present for all
Bernadette Li (BL)	NICE – Technical Adviser (HE)	Present for all
Vonda Murray (VM)	NICE – Project Manager	Present for all

Apologies:	
Julia Anderson	Committee member
Elizabeth Barrett (EB)	NICE – Information Specialist
Simon McPherson	Committee member

Observer:

Adrian Jonas

NICE – Associate Director
Healthcare Data AnalyticsPresent until part
way through item 6**1. Introductions and guideline committee working**

The Chair welcomed the Committee members and attendees to the 6th committee meeting on VTE diseases. The Committee members and attendees introduced themselves. The Chair informed the Committee that apologies had been received from those listed above.

The minutes were reviewed from Gcomm 5; Monday 29th and Tuesday 30th October 2018. Subject to the changes listed below, the minutes were agreed to be an accurate record.

- Location, change from London to Manchester
- Attendance – BL, attendance, which items she was present for

The Chair asked everyone to verbally declare any interests. No new interests were declared. The DOI register was made available to the Chair, and committee. The Chair reviewed and considered the DOI register. The Chair advised that FA could not contribute to the recommendation discussion for RQ 3.1, 3.2, 1.3 and 2.4, but could remain in the room. It was agreed that all other committee members were eligible to attend the committee meeting and contribute to the discussions and drafting of any recommendations.

The Chair outlined the objectives of the meeting; clinical introduction for a review question that will be presented at GComm7, along with evidence presentation and discussion for pharmacological treatments.

2. Clinical introduction to Review Question, 5.1**RQ5.1 What is the clinical and cost effectiveness of outpatient treatment for low-risk suspected or confirmed PE, and for whom is outpatient treatment safe?**

CH provided a clinical introduction on outpatient treatment for low-risk suspected or confirmed PE, and for whom is outpatient treatment safe. The Chair thanked CH for her presentation. The committee asked CH a number of questions.

**3. RQ 3.1: What is the clinical and cost effectiveness of different pharmacological treatments for people with a confirmed diagnosis of DVT?
RQ 3.2: What is the clinical and cost effectiveness of different pharmacological treatments for people with a confirmed diagnosis of PE?**

RQ 1.3: What is the clinical and cost effectiveness of different pharmacological treatments for people with suspected DVT prior to confirmed diagnosis?

RQ 2.4: What is the clinical and cost effectiveness of different pharmacological treatments for people with suspected PE prior to confirmed diagnosis?

- Revisit issues raised at last meeting

TJ and BL led a discussion with the committee about the issues raised at GComm5

4. Review Questions – RQ3.1, RQ3.2, RQ1.3, and RQ2.4

- Extended network evidence presentation
- Health Economics

TJ outlined how the pharmacological review questions had been split into 3 sections for analysis. He presented the pairwise clinical evidence for extended treatment, which covers treatment only in those that have already received 3-12 months treatment post diagnosis.

BJ presented to the committee the health economic evidence for extended treatment.

5. Review Questions – RQ3.1, RQ3.2, RQ1.3, and RQ2.4

- Cancer network evidence presentation
- Health Economics

TJ presented the presented the clinical evidence for the cancer subgroup for the pharmacological review questions, which only covers participants with cancer and VTE. This included consideration of the pairwise results and network meta-analysis results.

BJ presented to the committee the health economic evidence for the cancer subgroup for the pharmacological review questions.

6. Review Questions – RQ3.1, RQ3.2, RQ1.3, and RQ2.4

- Draft recommendations

The committee discussed the evidence presented, and reviewed and updated recommendations accordingly.

7. Next steps

The Chair confirmed the venue, date and time of the next meeting, as detailed below and thanked the Committee and others present for their contribution to the meeting before closing the meeting.

Date of next meeting: Monday 4th February 2019

Location of next meeting: NICE – Manchester